Evidence map›Paper›PMID 32777758›Full record

ReviewJournal of critical care2020

What every Intensivist should know about COVID-19 associated acute kidney injury.

Marlies Ostermann, Nuttha Lumlertgul, Lui G Forni, Eric Hoste

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of critical care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04997915 (Acute Kidney Injury in COVID-19 Patients Admitted to the ICU), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04997915 completednot on this map

Acute Kidney Injury in COVID-19 Patients Admitted to the ICU: a Multicenter Cohort Analysis in 9 Large Hospitals in Belgium

TypeobservationalSponsorUniversity Hospital, GhentRan2020 to 2022Enrolled1,286ConditionsCritical Illness, COVID-19 Pneumonia, Acute Kidney InjuryArmsObservational study exploring the epidemiology and outcomes of AKI in critical COVID-19 patients admitted to the ICU
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 3 countries.

Marlies OstermannDepartment of Critical Care, Guy's & St Thomas' Hospital, NHS Foundation Trust, London, UK. Electronic address: Marlies.Ostermann@gstt.nhs.uk.
Nuttha LumlertgulDepartment of Critical Care, Guy's & St Thomas' Hospital, NHS Foundation Trust, London, UK; Division of Nephrology, Department of Internal Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Excellence Center in Critical Care Nephrology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Critical Care Nephrology Research Unit, Chulalongkorn University, Bangkok, Thailand.
Lui G ForniCritical Care Unit, Royal Surrey Hospital NHS Foundation Trust, Department of Clinical & Experimental Medicine, University of Surrey, Guildford, UK.
Eric HosteDepartment of Intensive Care, Ghent University, Ghent, Belgium.
Chulalongkorn University · THGhent University Hospital · BESt Thomas' Hospital · GBUniversity of Surrey · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute kidney injury (AKI) is a serious complication in critically ill patients with COVID-19 with a reported incidence ranging from <5% to >25%. Proposed aetiologies include hypovolemia, hemodynamic disturbance and inflammation but also specific factors like direct viral invasion, microvascular thrombosis, and altered regulation of the renin-angiotensin-aldosterone system. To date, there are no confirmed specific therapies, and prevention and management of AKI should follow established guidelines. Novel therapies specifically targeting COVID-19 related pathologies are under investigation. The incidence of renal replacement therapy (RRT) is variable, ranging from 0-37%. In a pandemic, RRT practice is likely to be determined by the number of patients, availability of machines, consumables and staff, clinical expertise, and acceptable alternatives. Close collaboration between critical care and renal services is essential. In this article, we describe the epidemiology and pathophysiology of COVID-19 associated AKI, outline current management and suggest strategies to provide RRT during a pandemic when resources may be scarce.

Indexed as

Renal Replacement TherapyAcute Kidney InjuryAldosteroneAnticoagulantsCOVID-19Critical CareCritical IllnessHumansInflammationMicrocirculationPandemicsRenin-Angiotensin SystemRhabdomyolysisThrombosisTreatment OutcomeAldosteroneAnticoagulantsAcute kidney injuryCOVID-19PandemicRenal replacement therapy

Identifiers

PMID32777758
PMCPMC7386261
OpenAlexW3046198693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.